Base de dados : MEDLINE
Pesquisa : D27.505.696.620 [Categoria DeCS]
Referências encontradas : 609 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 61 ir para página                         

  1 / 609 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29278023
[Au] Autor:Clemente-Suárez VJ; Mielgo-Ayuso J; Quiles JL; Varela-Lopez A; Aranda P
[Ad] Endereço:1 Applied Psychophysiological Research Group, European University of Madrid , Madrid, Spain.
[Ti] Título:Effect of α-tocopherol megadoses on hematologic parameters and antioxidant capacity of rats in an ultraendurance probe.
[So] Source:Physiol Int;104(4):291-300, 2017 Dec 01.
[Is] ISSN:2498-602X
[Cp] País de publicação:Hungary
[La] Idioma:eng
[Ab] Resumo:This study was aimed to analyze the effect of two different megadoses of α-tocopherol (vit E) in the antioxidant activity and red and white blood series of Wistar rats after a 180-min ultraendurance probe. Three groups of 10 rats were analyzed; VEAG: acute administration of a megadoses of 5,000 IU/kg of vit E the day before the probe; VECG: chronic administration of 1,000 IU/kg/day of vit E for 6 days before the probe; CG: placebo administration. VEAG presented white cells, red blood cells, hematocrit, hemoglobin values significantly higher than CG and VECG (p < 0.05). The mean corpuscular hemoglobin and lymphocytes concentrations were significantly higher in the VECG than in the other two groups (p < 0.05). Similarly, VEAG presented a significantly higher vit E blood concentration than VECG and CG (p < 0.05), and VECG than CG (p < 0.05). Finally, we found a significantly positive correlation between trolox equivalent antioxidant capacity (TEAC) and red blood cells concentration (r = 0.374) and a significantly inverse correlation between TEAC and blood lactate concentration (r = -0.365). Our findings suggest that acute vit E megadoses could protect against transitory sport anemia symptoms and increase the white blood cell count in comparison with the chronic dose and control groups after an ultraendurance probe.
[Mh] Termos MeSH primário: Leucócitos/fisiologia
Substâncias para Melhoria do Desempenho/administração & dosagem
Resistência Física/efeitos dos fármacos
Resistência Física/fisiologia
Espécies Reativas de Oxigênio/metabolismo
Corrida/fisiologia
alfa-Tocoferol/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Antioxidantes/administração & dosagem
Relação Dose-Resposta a Droga
Eritrócitos/citologia
Eritrócitos/fisiologia
Hematócrito
Leucócitos/citologia
Masculino
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Performance-Enhancing Substances); 0 (Reactive Oxygen Species); H4N855PNZ1 (alpha-Tocopherol)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE
[do] DOI:10.1556/2060.104.2017.4.2


  2 / 609 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29183075
[Au] Autor:Van Wagoner RM; Eichner A; Bhasin S; Deuster PA; Eichner D
[Ad] Endereço:Sports Medicine Research and Testing Laboratory, Salt Lake City, Utah.
[Ti] Título:Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.
[So] Source:JAMA;318(20):2004-2010, 2017 11 28.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Recent reports have described the increasing use of nonsteroidal selective androgen receptor modulators, which have not been approved by the US Food and Drug Administration (FDA), to enhance appearance and performance. The composition and purity of such products is not known. Objective: To determine the chemical identity and the amounts of ingredients in dietary supplements and products marketed and sold through the internet as selective androgen receptor modulators and compare the analyzed contents with product labels. Design and Setting: Web-based searches were performed from February 18, 2016, to March 25, 2016, using the Google search engine on the Chrome and Internet Explorer web browsers to identify suppliers selling selective androgen receptor modulators. The products were purchased and the identities of the compounds and their amounts were determined from April to August 2016 using chain-of-custody and World Anti-Doping Association-approved analytical procedures. Analytical findings were compared against the label information. Exposures: Products marketed and sold as selective androgen receptor modulators. Main Outcomes and Measures: Chemical identities and the amount of ingredients in each product marketed and sold as selective androgen receptor modulators. Results: Among 44 products marketed and sold as selective androgen receptor modulators, only 23 (52%) contained 1 or more selective androgen receptor modulators (Ostarine, LGD-4033, or Andarine). An additional 17 products (39%) contained another unapproved drug, including the growth hormone secretagogue ibutamoren, the peroxisome proliferator-activated receptor-δ agonist GW501516, and the Rev-ErbA agonist SR9009. Of the 44 tested products, no active compound was detected in 4 (9%) and substances not listed on the label were contained in 11 (25%). In only 18 of the 44 products (41%), the amount of active compound in the product matched that listed on the label. The amount of the compounds listed on the label differed substantially from that found by analysis in 26 of 44 products (59%). Conclusions and Relevance: In this limited investigation involving chemical analyses of 44 products marketed as selective androgen receptor modulators and sold via the internet, most products contained unapproved drugs and substances. Only 52% contained selective androgen receptor modulators and many were inaccurately labeled.
[Mh] Termos MeSH primário: Anabolizantes/química
Comércio
Rotulagem de Medicamentos
Internet
Substâncias para Melhoria do Desempenho/química
Receptores Androgênicos
[Mh] Termos MeSH secundário: Acetamidas/análise
Aminofenóis/análise
Anilidas/análise
Aprovação de Drogas
Tráfico de Drogas
Nitrilos/análise
Pirrolidinas/análise
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (4-(2-(2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-(trifluoromethyl)benzonitrile); 0 (Acetamides); 0 (Aminophenols); 0 (Anabolic Agents); 0 (Anilides); 0 (Nitriles); 0 (Performance-Enhancing Substances); 0 (Pyrrolidines); 0 (Receptors, Androgen); 7UT2HAH49H (andarine); O3571H3R8N (ostarine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.17069


  3 / 609 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29183050
[Au] Autor:Auchus RJ; Brower KJ
[Ad] Endereço:Division of Metabolism, Diabetes, and Endocrinology, Department of Internal Medicine, University of Michigan, Ann Arbor.
[Ti] Título:The Public Health Consequences of Performance-Enhancing Substances: Who Bears Responsibility?
[So] Source:JAMA;318(20):1983-1984, 2017 11 28.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Substâncias para Melhoria do Desempenho
Comportamento Social
[Mh] Termos MeSH secundário: Atletas
Seres Humanos
Responsabilidade Social
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Performance-Enhancing Substances)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.17111


  4 / 609 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465675
[Au] Autor:McLeay Y; Stannard S; Houltham S; Starck C
[Ad] Endereço:School of Sport and Exercise, Massey University, Private Bag 11-222, Palmerston North, New Zealand.
[Ti] Título:Dietary thiols in exercise: oxidative stress defence, exercise performance, and adaptation.
[So] Source:J Int Soc Sports Nutr;14:12, 2017.
[Is] ISSN:1550-2783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Endurance athletes are susceptible to cellular damage initiated by excessive levels of aerobic exercise-produced reactive oxygen species (ROS). Whilst ROS can contribute to the onset of fatigue, there is increasing evidence that they play a crucial role in exercise adaptations. The use of antioxidant supplements such as vitamin C and E in athletes is common; however, their ability to enhance performance and facilitate recovery is controversial, with many studies suggesting a blunting of training adaptations with supplementation. The up-regulation of endogenous antioxidant systems brought about by exercise training allows for greater tolerance to subsequent ROS, thus, athletes may benefit from increasing these systems through dietary thiol donors. Recent work has shown supplementation with a cysteine donor (N-acetylcysteine; NAC) improves antioxidant capacity by augmenting glutathione levels and reducing markers of oxidative stress, as well as ergogenic potential through association with delayed fatigue in numerous experimental models. However, the use of this, and other thiol donors may have adverse physiological effects. A recent discovery for the use of a thiol donor food source, keratin, to potentially enhance endogenous antioxidants may have important implications for endurance athletes hoping to enhance performance and recovery without blunting training adaptations.
[Mh] Termos MeSH primário: Adaptação Fisiológica/efeitos dos fármacos
Desempenho Atlético
Dieta
Exercício/fisiologia
Estresse Oxidativo
Compostos de Sulfidrila/administração & dosagem
[Mh] Termos MeSH secundário: Antioxidantes/administração & dosagem
Antioxidantes/metabolismo
Atletas
Seres Humanos
Substâncias para Melhoria do Desempenho/administração & dosagem
Espécies Reativas de Oxigênio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antioxidants); 0 (Performance-Enhancing Substances); 0 (Reactive Oxygen Species); 0 (Sulfhydryl Compounds)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12970-017-0168-9


  5 / 609 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28533317
[Au] Autor:Baggish AL; Weiner RB; Kanayama G; Hudson JI; Lu MT; Hoffmann U; Pope HG
[Ad] Endereço:From Cardiovascular Performance Program, Division of Cardiology, Massachusetts General Hospital, Boston (A.L.B., R.B.W.); Department of Medicine, Harvard Medical School, Boston, MA (A.L.B., R.B.W.); Biological Psychiatry Laboratory and Psychiatric Epidemiology Research Program, McLean Hospital, Belm
[Ti] Título:Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use.
[So] Source:Circulation;135(21):1991-2002, 2017 May 23.
[Is] ISSN:1524-4539
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Millions of individuals have used illicit anabolic-androgenic steroids (AAS), but the long-term cardiovascular associations of these drugs remain incompletely understood. METHODS: Using a cross-sectional cohort design, we recruited 140 experienced male weightlifters 34 to 54 years of age, comprising 86 men reporting ≥2 years of cumulative lifetime AAS use and 54 nonusing men. Using transthoracic echocardiography and coronary computed tomography angiography, we assessed 3 primary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction), LV diastolic function (early relaxation velocity), and coronary atherosclerosis (coronary artery plaque volume). RESULTS: Compared with nonusers, AAS users demonstrated relatively reduced LV systolic function (mean±SD left ventricular ejection fraction = 52±11% versus 63±8%; <0.001) and diastolic function (early relaxation velocity = 9.3±2.4 cm/second versus 11.1±2.0 cm/second; <0.001). Users currently taking AAS at the time of evaluation (N=58) showed significantly reduced LV systolic (left ventricular ejection fraction = 49±10% versus 58±10%; <0.001) and diastolic function (early relaxation velocity = 8.9±2.4 cm/second versus 10.1±2.4 cm/second; =0.035) compared with users currently off-drug (N=28). In addition, AAS users demonstrated higher coronary artery plaque volume than nonusers (median [interquartile range] 3 [0, 174] mL versus 0 [0, 69] mL ; =0.012). Lifetime AAS dose was strongly associated with coronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 10-year increase in cumulative duration of AAS use: 0.60 SD units [0.16-1.03 SD units]; =0.008). CONCLUSIONS: Long-term AAS use appears to be associated with myocardial dysfunction and accelerated coronary atherosclerosis. These forms of AAS-associated adverse cardiovascular phenotypes may represent a previously underrecognized public-health problem.
[Mh] Termos MeSH primário: Androgênios/efeitos adversos
Doença da Artéria Coronariana/induzido quimicamente
Vasos Coronários/efeitos dos fármacos
Doping nos Esportes
Substâncias para Melhoria do Desempenho/efeitos adversos
Transtornos Relacionados ao Uso de Substâncias/complicações
Congêneres da Testosterona/efeitos adversos
Disfunção Ventricular Esquerda/induzido quimicamente
Função Ventricular Esquerda/efeitos dos fármacos
Levantamento de Peso
[Mh] Termos MeSH secundário: Adulto
Cardiotoxicidade
Estudos de Casos e Controles
Angiografia por Tomografia Computadorizada
Angiografia Coronária/métodos
Doença da Artéria Coronariana/diagnóstico por imagem
Doença da Artéria Coronariana/patologia
Vasos Coronários/diagnóstico por imagem
Vasos Coronários/patologia
Estudos Transversais
Diástole
Ecocardiografia
Seres Humanos
Masculino
Meia-Idade
Tomografia Computadorizada Multidetectores
Placa Aterosclerótica
Medição de Risco
Fatores de Risco
Volume Sistólico/efeitos dos fármacos
Sístole
Fatores de Tempo
Disfunção Ventricular Esquerda/diagnóstico por imagem
Disfunção Ventricular Esquerda/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Androgens); 0 (Performance-Enhancing Substances); 0 (Testosterone Congeners)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170524
[St] Status:MEDLINE
[do] DOI:10.1161/CIRCULATIONAHA.116.026945


  6 / 609 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28346571
[Au] Autor:Tallis J; James RS; Cox VM; Duncan MJ
[Ad] Endereço:Jason Tallis, Research Centre for Applied Biological and Exercise Sciences, James Starley Building, Coventry University, Priory Street, Coventry CV1 5FB, United Kingdom, Email: tallisj2@uni.coventry.ac.uk.
[Ti] Título:Is the Ergogenicity of Caffeine Affected by Increasing Age? The Direct Effect of a Physiological Concentration of Caffeine on the Power Output of Maximally Stimulated EDL and Diaphragm Muscle Isolated from the Mouse.
[So] Source:J Nutr Health Aging;21(4):440-448, 2017.
[Is] ISSN:1760-4788
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Caffeine is a well-established performance enhancing nutritional supplement in a young healthy population, however far less is known about how its ergogenicity is affected by increasing age. A recent review has highlighted the value of studies examining the direct effect of caffeine on isolated skeletal muscle contractility, but the present work is the first to assess the direct effect of 70µM caffeine (physiological maximum) on the maximal power output of isolated mammalian muscle from an age range representing developmental to early ageing. METHOD: Female CD1 mice were aged to 3, 10, 30 and 50 weeks (n = 20 in each case) and either whole EDL or a section of the diaphragm was isolated and maximal power output determined using the work loop technique. Once contractile performance was maximised, each muscle preparation was treated with 70µM caffeine and its contractile performance was measured for a further 60 minutes. RESULTS: In both mouse EDL and diaphragm 70µM caffeine treatment resulted in a significant increase in maximal muscle power output that was greatest at 10 or 30 weeks (up to 5% and 6% improvement respectively). This potentiation of maximal muscle power output was significantly lower at the early ageing time point, 50 weeks (up to 3% and 2% improvement respectively), and in mice in the developmental stage, at 3 weeks of age (up to 1% and 2% improvement respectively). CONCLUSION: Uniquely, the present findings indicate a reduced age specific sensitivity to the performance enhancing effect of caffeine in developmental and aged mice which is likely to be attributed to age related muscle growth and degradation, respectively. Importantly, the findings indicate that caffeine may still provide a substantial ergogenic aid in older populations which could prove important for improving functional capacity in tasks of daily living.
[Mh] Termos MeSH primário: Cafeína/farmacologia
Diafragma/fisiologia
Contração Muscular/fisiologia
Fadiga Muscular/efeitos dos fármacos
Substâncias para Melhoria do Desempenho/farmacologia
[Mh] Termos MeSH secundário: Envelhecimento
Animais
Feminino
Camundongos
Sarcopenia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Performance-Enhancing Substances); 3G6A5W338E (Caffeine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.1007/s12603-016-0832-9


  7 / 609 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28287486
[Au] Autor:Salinero JJ; Lara B; Ruiz-Vicente D; Areces F; Puente-Torres C; Gallo-Salazar C; Pascual T; Del Coso J
[Ad] Endereço:Exercise Physiology Laboratory, Camilo José Cela University, Madrid 28692, Spain. jjsalinero@ucjc.edu.
[Ti] Título:CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study.
[So] Source:Nutrients;9(3), 2017 Mar 11.
[Is] ISSN:2072-6643
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Previous investigations have determined that some individuals have minimal or even ergolytic performance effects after caffeine ingestion. The aim of this study was to analyze the influence of the genetic variations of the CYP1A2 gene on the performance enhancement effects of ingesting a moderate dose of caffeine. In a double-blind randomized experimental design, 21 healthy active participants (29.3 ± 7.7 years) ingested 3 mg of caffeine per kg of body mass or a placebo in testing sessions separated by one week. Performance in the 30 s Wingate test, visual attention, and side effects were evaluated. DNA was obtained from whole blood samples and the CYP1A2 polymorphism was analyzed (rs762551). We obtained two groups: AA homozygotes ( = 5) and C-allele carriers ( = 16). Caffeine ingestion increased peak power (682 ± 140 vs. 667 ± 137 W; = 0.008) and mean power during the Wingate test (527 ± 111 vs. 518 ± 111 W; < 0.001) with no differences between AA homozygotes and C-allele carriers ( > 0.05). Reaction times were similar between caffeine and placebo conditions (276 ± 31 vs. 269 ± 71 milliseconds; = 0.681) with no differences between AA homozygotes and C-allele carriers. However, 31.3% of the C-allele carriers reported increased nervousness after caffeine ingestion, while none of the AA homozygotes perceived this side effect. Genetic variations of the CYP1A2 polymorphism did not affect the ergogenic effects and drawbacks derived from the ingestion of a moderate dose of caffeine.
[Mh] Termos MeSH primário: Ansiedade/etiologia
Cafeína/efeitos adversos
Citocromo P-450 CYP1A2/genética
Suplementos Nutricionais/efeitos adversos
Exercício
Substâncias para Melhoria do Desempenho/efeitos adversos
[Mh] Termos MeSH secundário: Região 5'-Flanqueadora
Adulto
Alelos
Atenção
Cafeína/administração & dosagem
Cafeína/metabolismo
Citocromo P-450 CYP1A2/metabolismo
Método Duplo-Cego
Feminino
Estudos de Associação Genética
Heterozigoto
Homozigoto
Seres Humanos
Masculino
Substâncias para Melhoria do Desempenho/administração & dosagem
Substâncias para Melhoria do Desempenho/metabolismo
Projetos Piloto
Polimorfismo de Nucleotídeo Único
Espanha
Percepção Visual
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Performance-Enhancing Substances); 3G6A5W338E (Caffeine); EC 1.14.14.1 (CYP1A2 protein, human); EC 1.14.14.1 (Cytochrome P-450 CYP1A2)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170823
[Lr] Data última revisão:
170823
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE


  8 / 609 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28215405
[Au] Autor:Kwok WH; Choi TLS; Tsoi YYK; Leung GNW; Wan TSM
[Ad] Endereço:Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong, China. Electronic address: wh.kwok@hkjc.org.hk.
[Ti] Título:Screening of over 100 drugs in horse urine using automated on-line solid-phase extraction coupled to liquid chromatography-high resolution mass spectrometry for doping control.
[So] Source:J Chromatogr A;1490:89-101, 2017 Mar 24.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A fast method for the direct analysis of enzyme-hydrolysed horse urine using an automated on-line solid-phase extraction (SPE) coupled to a liquid-chromatography/high resolution mass spectrometer was developed. Over 100 drugs of diverse drug classes could be simultaneously detected in horse urine at sub to low parts per billion levels. Urine sample was first hydrolysed by ß-glucuronidase to release conjugated drugs, followed by centrifugal filtration. The filtrate (1mL) was directly injected into an on-line SPE system consisting of a pre-column filter and a SPE cartridge column for the separation of analytes from matrix components. Through valves-switching, the interfering matrix components were flushed to waste, and the analytes were eluted to a C analytical column for refocusing and chromatographic separation. Detections were achieved by full-scan HRMS in alternating positive and negative electrospray ionisation modes within a turn-around time of 16min, inclusive of on-line sample clean-up and post-run mobile phase equilibration. No significant matrix interference was observed at the expected retention times of the targeted masses. Over 90% of the drugs studied gave estimated limits of detection (LoDs) at or below 5ng/mL, with some LoDs reaching down to 0.05ng/mL. Data-dependent acquisition (DDA) was included to provide additional product-ion scan data to substantiate the presence of detected analytes. The resulting product-ion spectra can be searched against an in-house MS/MS library for identity verification. The applicability of the method has been demonstrated by the detection of drugs in doping control samples.
[Mh] Termos MeSH primário: Cromatografia Líquida/veterinária
Doping nos Esportes
Substâncias para Melhoria do Desempenho/urina
Extração em Fase Sólida/veterinária
Detecção do Abuso de Substâncias/métodos
Espectrometria de Massas em Tandem/veterinária
[Mh] Termos MeSH secundário: Animais
Cromatografia Líquida de Alta Pressão/métodos
Cromatografia Líquida/métodos
Glucuronidase
Cavalos
Limite de Detecção
Extração em Fase Sólida/métodos
Espectrometria de Massas em Tandem/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Performance-Enhancing Substances); EC 3.2.1.31 (Glucuronidase)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170910
[Lr] Data última revisão:
170910
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170221
[St] Status:MEDLINE


  9 / 609 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28177725
[Au] Autor:Gonzalez AM; Sell KM; Ghigiarelli JJ; Kelly CF; Shone EW; Accetta MR; Baum JB; Mangine GT
[Ad] Endereço:a Department of Health Professions, Hofstra University, Hempstead, NY 11549, USA.
[Ti] Título:Effects of phosphatidic acid supplementation on muscle thickness and strength in resistance-trained men.
[So] Source:Appl Physiol Nutr Metab;42(4):443-448, 2017 Apr.
[Is] ISSN:1715-5320
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to investigate the effects of phosphatidic acid (PA) supplementation on muscle thickness and strength following an 8 week supervised resistance-training program. Fifteen resistance trained men (22.8 ± 3.5 years; 80.6 ± 8.7 kg; 178.1 ± 5.6 cm; 14.6% ± 8.8% body fat) were randomly assigned to a group that either consumed 750 mg of PA or a placebo (PL). Testing was carried out before (PRE) and after (POST) training/supplementation for muscle thickness and strength. Muscle thickness of the rectus femoris (RF), vastus lateralis (VL), biceps brachii (BB), and triceps brachii (TB) muscles were measured via ultrasonography, along with 1 repetition maximum (1RM) of squat, deadlift, and bench press. Analysis of covariance (ANCOVA), using PRE values as the covariate, did not reveal any group differences for measures of muscle thickness in the RF (PA: 3.6% ± 5.2%; PL: 3.2% ± 4.2%, p = 0.97), VL (PA: 23.4% ± 18.1%, PL: 12.5% ± 15.4%, p = 0.37), BB (PA: 3.7% ± 6.4%, PL: 9.6% ± 12.4%, p = 0.86), or TB (PA: 15.1% ± 17.9%, PL: 10.7% ± 19.3%, p = 0.79). Likewise, no group differences were observed in changes in squat (PA: 8.4% ± 4.1%, PL: 8.1% ± 4.2%, p = 0.79), deadlift (PA: 10.1% ± 10.1%, PL: 8.9% ± 9.5%, p = 0.66), or bench press (PA: 5.7% ± 5.5%, PL: 5.1% ± 3.0%, p = 0.76) exercises. Collectively, however, all participants experienced significant (p < 0.05) improvements in each measure of muscle thickness and strength. Results of this study suggest that PA supplementation, in combination with a 3 days·week resistance-training program for 8 weeks, did not have a differential effect compared with PL on changes in muscle thickness or 1RM strength.
[Mh] Termos MeSH primário: Desempenho Atlético
Suplementos Nutricionais
Desenvolvimento Muscular
Força Muscular
Substâncias para Melhoria do Desempenho/administração & dosagem
Ácidos Fosfatídicos/administração & dosagem
Treinamento de Resistência
[Mh] Termos MeSH secundário: Adulto
Atletas
Gorduras na Dieta/administração & dosagem
Gorduras na Dieta/efeitos adversos
Suplementos Nutricionais/efeitos adversos
Método Duplo-Cego
Seres Humanos
Masculino
Músculo Esquelético/diagnóstico por imagem
Músculo Esquelético/crescimento & desenvolvimento
Cooperação do Paciente
Substâncias para Melhoria do Desempenho/efeitos adversos
Ácidos Fosfatídicos/efeitos adversos
Reprodutibilidade dos Testes
Ultrassonografia
Levantamento de Peso
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dietary Fats); 0 (Performance-Enhancing Substances); 0 (Phosphatidic Acids)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170830
[Lr] Data última revisão:
170830
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170209
[St] Status:MEDLINE
[do] DOI:10.1139/apnm-2016-0564


  10 / 609 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28160745
[Au] Autor:Pretegiani E; Rosini F; Rocchi R; Ginanneschi F; Vinciguerra C; Optican LM; Rufa A
[Ad] Endereço:Eye Tracking and Visual Application Laboratory (EVALab), Unit of Neurology and Metabolic Diseases, Department of Medical, Surgical, and Neurological Sciences, University of Siena, Italy; Laboratory of Sensorimotor Research, IRP, National Eye Institute, National Institutes of Health, Bethesda, MD, US
[Ti] Título:GABAAergic dysfunction in the olivary-cerebellar-brainstem network may cause eye oscillations and body tremor.
[So] Source:Clin Neurophysiol;128(3):408-410, 2017 03.
[Is] ISSN:1872-8952
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Tronco Encefálico/fisiopatologia
Cerebelo/fisiopatologia
Transtornos da Motilidade Ocular/fisiopatologia
Núcleo Olivar/fisiopatologia
Substâncias para Melhoria do Desempenho/efeitos adversos
Tremor/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Masculino
Transtornos da Motilidade Ocular/induzido quimicamente
Tremor/etiologia
[Pt] Tipo de publicação:CASE REPORTS; LETTER; RESEARCH SUPPORT, N.I.H., INTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
0 (Performance-Enhancing Substances)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170205
[St] Status:MEDLINE



página 1 de 61 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde